éå»1ã¶æéã«Chemomab Therapeutics Ltdã«å¯ŸããŠè©äŸ¡ãåºããã¢ããªã¹ã2åã«åºã¥ãããŒã¿ã
仿ãCMMBã¯1ä»¶ã®ãè²·ããã0ä»¶ã®ãäžç«ïŒããŒã«ãïŒãã0ä»¶ã®ã売ããè©äŸ¡ãç²åŸããŸãããçŽè¿1ã¶æã«ãããCMMBã®ã¢ããªã¹ãå¹³åç®æšæ ªäŸ¡ã¯15.000ã§ãã
ã¢ããªã¹ãäºæ³ã«ãããšãFY2026Q2ã«çºè¡šãããEPS -0.270ã«ç¶ããCMMBã®FY2026Q3ã®EPSã¯-0.115ã«éããèŠéãã§ããçºè¡šãããå®çžŸå€ãšäºæ³ãæ¯èŒããŠãåçæ§ã®æšç§»ã確èªããŸãããã
åžå Žäºæ³ã¯ USD -0.27 ã§ããããChemomab Therapeutics LtdCMMB ã®åååæã®äžæ ªåœããå©ç (EPS) 㯠USD -0.22 ã§ãããæ¬¡ã®ååæã® EPS 㯠USD -0.12 ãšäºæ³ãããŸãã